清热利湿通络法治疗早期糖尿病肾病的临床研究
|
摘要
目的：在新加坡(仁康中医诊疗中心)门诊按照一般临床设计研究,观察以清热利湿通络法治疗早期糖尿病肾病湿瘀阻络证患者中医临床症状、蛋白尿、肾功能、血糖、血脂、血红蛋白及血桨白蛋白的改善,探讨清热利湿通络法治疗早期糖尿病肾病的机理。评价在西医降糖、控制血压等基础治疗的基础上清热利湿通络中药对糖尿病肾病(DN)患者尿蛋白和肾功能的影响。
方法：将符合西医诊断标准和中医辨证标准的48例患者分为治疗组26例和对照组22例。治疗组在原有西药不变的基础上,加用清热利湿通络中成药(处方是均以《台湾港香兰》生产“浓缩科学细粒剂Granules")和《台湾顺天堂》生产的特浓缩细粒,处方：黄芩1.5g、茯苓2g、泽泻1g、怀牛膝1g、丝瓜络2g、玉米须2g、丹参1g、益母草1g,生大黄1.5g。注(每1克浓缩科学细粒剂相等于原药生药3.5克。每日两次,早晚口服,治疗10周后评价其疗效。对照组,则维持原有的西药治疗。连续观察10周。
结果：研究显示,中医药的疗效机理是通过多靶点多器官系统的整体调节而实现的,因此其治疗效果通常在症状体征和实验室指标两个方面都有反映。本研究中疾病治疗总有效率为92.3%,与对照组(总有效率为54.54%)有非常显著的差异。说明以清热利湿通络方在西药治疗的基础上,既可进一步改善早期糖尿病肾病湿瘀阻络证病患者的血糖及血脂代谢,又能明显改善患者的湿瘀阻络的症状和体征,使患者的疾病状态得到较全面地改观
治疗前后的组内比较显示,治疗组在糖化血红蛋白(HbAIC)、空腹血糖(FBG)和餐后2小时血糖(PBG)方面均有极其显著性差异(P<0.001),总胆固醇(TC)和低密度脂蛋白(LDL)有极其显著性差异(P<0.001),甘油三酯(TG)有显著性差异(P<0.05)。而对照组治疗前与治疗后没有显著性差异。
分析：清热利湿通络法,从整体的角度改善身体的素质,改善气血的运行,调节新陈代谢。现代研究证实,本研究所选用的大多数中药物具有良好的降血糖、降血脂、和改善胰岛素抵抗及血液流变学等多方位的、多环节的作用。因此,在患者的西药治疗表现出进展停顿时,中医药的介入不仅使血糖进一步降低,而且明显改善临床症状,说明清热利湿通络法不仅能增强体质,提升能量,还能促进机体的能量物质代谢。
结论：清热利湿通络法对早期糖尿病肾病患者的中医临床症状、糖化血红蛋白,空腹血糖和餐后2小时血糖及生活质量疗效明显。
In Diabetic nephropathy (Diabetic Nephropathy, DN), diabetic glomerulosclerosis is one of the most typical diabetes microvascular complications. It is the main reason leading to the death of diabetic patients. Diabetic nephropathy in about20%to40%of type1or type2diabetes patients with some progressing to End Stage Renal Disease (ESRD) Without special intervention, approximately80%of people with persistent microalbuminuria in type1diabetes in10to15years, develop clinical nephropathy accompanied with hypertension. Once clinical nephropathy occurs, and lack of effective intervention, glomerular filtration rate can gradually deteriorate within a few years, gradually decreased to50%after10years, and20years later, more than75%of patients will develop ESRD.
Objective:The clinical research, made observations of the effects of expulsion of heat dampness through collaterals in the treatment of early diabetic nephropathy patients, understands the impact of the TCM clinical symptoms, proteinuria, kidney function, blood sugar, blood lipids, hemoglobin and plasma albumin mechanism for the above treatment of early diabetic nephropathy.
Methods:48patients were in line with Western diagnostic criteria and standards of TCM is divided into22cases of26cases of the treatment group and control group. Treatment group maintain the same in the original Western medicine, with added clearing away heat and Tongluo Chinese medicine treatment, twice daily, morning and evening oral. Evaluation was carried out after10weeks of treatment. Control group, maintain the original western medicine. Continuous observation for made for10weeks.
Results:After treatment, Chinese medicine clinical symptoms total score than before treatment there are significant differences in the control group, P<0.05, treatment group, P<0.001, between groups after treatment, the contrast is extremely significant difference (P<0.001), treatment group efficiency of92.3%.
Conclusion:clearing away heat and collaterals of TCM clinical symptoms in patients with early diabetic nephropathy, glycated hemoglobin, fasting plasma glucose and2-hour postprandial blood glucose and quality of life were significantly improved.
方法：将符合西医诊断标准和中医辨证标准的48例患者分为治疗组26例和对照组22例。治疗组在原有西药不变的基础上,加用清热利湿通络中成药(处方是均以《台湾港香兰》生产“浓缩科学细粒剂Granules")和《台湾顺天堂》生产的特浓缩细粒,处方：黄芩1.5g、茯苓2g、泽泻1g、怀牛膝1g、丝瓜络2g、玉米须2g、丹参1g、益母草1g,生大黄1.5g。注(每1克浓缩科学细粒剂相等于原药生药3.5克。每日两次,早晚口服,治疗10周后评价其疗效。对照组,则维持原有的西药治疗。连续观察10周。
结果：研究显示,中医药的疗效机理是通过多靶点多器官系统的整体调节而实现的,因此其治疗效果通常在症状体征和实验室指标两个方面都有反映。本研究中疾病治疗总有效率为92.3%,与对照组(总有效率为54.54%)有非常显著的差异。说明以清热利湿通络方在西药治疗的基础上,既可进一步改善早期糖尿病肾病湿瘀阻络证病患者的血糖及血脂代谢,又能明显改善患者的湿瘀阻络的症状和体征,使患者的疾病状态得到较全面地改观
治疗前后的组内比较显示,治疗组在糖化血红蛋白(HbAIC)、空腹血糖(FBG)和餐后2小时血糖(PBG)方面均有极其显著性差异(P<0.001),总胆固醇(TC)和低密度脂蛋白(LDL)有极其显著性差异(P<0.001),甘油三酯(TG)有显著性差异(P<0.05)。而对照组治疗前与治疗后没有显著性差异。
分析：清热利湿通络法,从整体的角度改善身体的素质,改善气血的运行,调节新陈代谢。现代研究证实,本研究所选用的大多数中药物具有良好的降血糖、降血脂、和改善胰岛素抵抗及血液流变学等多方位的、多环节的作用。因此,在患者的西药治疗表现出进展停顿时,中医药的介入不仅使血糖进一步降低,而且明显改善临床症状,说明清热利湿通络法不仅能增强体质,提升能量,还能促进机体的能量物质代谢。
结论：清热利湿通络法对早期糖尿病肾病患者的中医临床症状、糖化血红蛋白,空腹血糖和餐后2小时血糖及生活质量疗效明显。
In Diabetic nephropathy (Diabetic Nephropathy, DN), diabetic glomerulosclerosis is one of the most typical diabetes microvascular complications. It is the main reason leading to the death of diabetic patients. Diabetic nephropathy in about20%to40%of type1or type2diabetes patients with some progressing to End Stage Renal Disease (ESRD) Without special intervention, approximately80%of people with persistent microalbuminuria in type1diabetes in10to15years, develop clinical nephropathy accompanied with hypertension. Once clinical nephropathy occurs, and lack of effective intervention, glomerular filtration rate can gradually deteriorate within a few years, gradually decreased to50%after10years, and20years later, more than75%of patients will develop ESRD.
Objective:The clinical research, made observations of the effects of expulsion of heat dampness through collaterals in the treatment of early diabetic nephropathy patients, understands the impact of the TCM clinical symptoms, proteinuria, kidney function, blood sugar, blood lipids, hemoglobin and plasma albumin mechanism for the above treatment of early diabetic nephropathy.
Methods:48patients were in line with Western diagnostic criteria and standards of TCM is divided into22cases of26cases of the treatment group and control group. Treatment group maintain the same in the original Western medicine, with added clearing away heat and Tongluo Chinese medicine treatment, twice daily, morning and evening oral. Evaluation was carried out after10weeks of treatment. Control group, maintain the original western medicine. Continuous observation for made for10weeks.
Results:After treatment, Chinese medicine clinical symptoms total score than before treatment there are significant differences in the control group, P<0.05, treatment group, P<0.001, between groups after treatment, the contrast is extremely significant difference (P<0.001), treatment group efficiency of92.3%.
Conclusion:clearing away heat and collaterals of TCM clinical symptoms in patients with early diabetic nephropathy, glycated hemoglobin, fasting plasma glucose and2-hour postprandial blood glucose and quality of life were significantly improved.
引文
1.MogensenCE.Natural history of renalfunctionalabnormal aties in human diabetesmellitus from norm albuminuria toincipient and overt nephropathy.The Kidneyin Diabetes Mellitus. New York Livingstone,1989; 19.
2.毛黎明,俞东容,涂晓.辨证与辨病相结合治疗糖尿病肾病32例.浙江中医学院学报,25(N)：17-18.
3.张甲臣.浅谈糖尿病肾病的中医治疗.河南中医,1999,19(J)：21.
4.周恩庆.王西周老师治疗糖尿病肾病经验介绍.陕西中医,2001,22(J)：225-226.
5.陈以平.肾病的辨证与辨病治疗.人民卫生出版社(J),2003,147-148.
6.沈稚舟,吴松华,邵福源，陈国辉主编.糖尿病慢性并发症.上海：上海医科大学出版社(J),1999,175-176.
7.吕贵德.辨证论治糖尿病肾病38例疗效观察.河北中医(J),2002,24：103-104.
8.刘从明，何金霞.辨证治疗糖尿病肾病临床观察.内蒙古中医药(J),1996,3：4-6.
9.张珍先,宋小平.糖尿病肾病的辨证施治.光明中医(J),2006,21(1)：16.
10.成秀梅.任琢珊治疗糖尿病肾病的经验.陕西中医(J),2003,24(10)：921.
11.鲁盈,楼狄.糖尿病肾病的诊断与中医治疗.浙江中西医结合杂志(J).1997,7(4)：201-203.
12.邓经林.48例糖尿病肾病的中医辨证论治.江西中医药(N),2001,32(5)：29.
13.郑庆媛.糖尿病肾病辨证分型论治.实用中医内科杂志(J)。2003,17(2)：72.
14.王改勤,姚丽,张寒梅.辨证治疗糖尿病肾病体会.江西中医药(J)，2004,35(8)：49.
15.傅能,赵韧.中西医结合治疗早期糖尿病肾病临床观察.现代中西医结合杂志(J),2006,15(8)：989.
16.罗月中.叶任高教授治疗糖尿病肾病的经验.中国中西医结合肾病杂志(J),2001,2(8)438-440.
17.郭连川.辨证治疗糖尿病性肾病54例.辽宁中医杂志(J),1993,3：19-20.
18.赵宗江.叶传蕙教授治疗糖尿病肾病的思路与方法.中国中西医结合肾病杂志(J),2006,7(3)：129-131.
19.张庚良.糖尿病肾病的辨证治疗.河北中医(S),2005,27(8)：594.
20.苏小惠,戴舜珍.中西医结合治疗糖尿病肾病40例临床观察.辽宁中医杂志(J),2006,33(1)92-93.
21.仝小林,张志远,李宁.等.糖尿病肾病的中医治疗.中国医药学报(N),1998,13(4)50-53.
22.南一,南红梅,何泽.南征教授治疗消渴肾病(糖尿病肾病)的经验.长春中医学院学报(N),2004,20(3)：8-9.
23.宋述菊,牟宗秀.糖尿病肾病病因病机及辨治探讨.山东中医杂志(J),1999,18(4)147-148.
24.张玉璞,刘玉英.辨证治疗糖尿病肾病.河北中医(S),1999,21(5)：292.
25.赵会贤,苏荣华,高新业.糖尿病肾病的病因病机及证治浅识.中医药学刊(J),2004,22(9)：1760-1763.
26.张瑞彬,糖尿病肾病中医辨治体会.河南中医,2003年,23(9)：66-67.
27.于晓光,王业丽,张琪.张琪教授辨治糖尿病肾病经验介绍.陕西中医(S),2004,25(12)：1116-1118.
28王晓光,王业丽.张佩清.张琪教授辨治糖尿病肾病经验介绍新中医[N],2005年37(3)20-21
29.梁炜,李世华.糖尿病肾病的发病机理和辨治思路.四川中医[N],2003,21(7)：7-8.
30.李大钧,范克.糖尿病肾病的中医辨证治疗.河北中医[S],2001,23(9)：682.
31.王立新.杨霓芝主任医师治疗糖尿病肾病经验拾萃.中医药研究[J],2000,16(6)：36.
32.杨霓芝,李芳,徐大基,等,糖尿病肾病分期辨证治疗的探讨,辽宁中医杂志[J],1999,26(1)：16-17.
33.詹锐文,李敬.糖尿病肾病的中医分型辨治浅析.实用中医内科杂志[J],2004,18卷(6)：566-567.
34.丁学屏.糖尿病病治疗方法举要.世界中医药学会联合会糖尿病专业委员会第二次国际中医糖尿病学术交流会论文集[A],2006,104-106.
35.林兰.糖尿病中西医结合论治.北京：北京科学技术出版社[M],1997,404-407.
36.倪青.著名中医学家林兰教授学术经验系列之四病机以气阴两虚为主治疗当益气养阴为先—治疗糖尿病肾病的经验整理.辽宁中医杂志[J],2000,27(4)：145-146.
37.孙炜.早期糖尿病肾病的中医辨证治疗.浙江中医学院学报[J],1999,2(4)：14.
38.董兴刚.张庆怡治疗早期糖尿病肾病临床经验.浙江中西医结合杂志,2005,15(12)751.
39.孙伟,何伟明.糖尿病肾病蛋白尿的中医药治疗体会.江苏中医药,2002,23(5)18-19.
40.任爱华,剥方旭.糖尿病肾病二焦辨治,山东中医杂志[J].2000,19(6)：328-329.
41.高阳,李琪.刘启庭辨治糖尿病肾病经验.河南中医[M],1997,17(1)：31-32.
42.张彤.名医经验叶景华主任治疗糖尿病肾病的临床经验.中医药信息[J],2003,20(3)：29-30.
43.翁荃,张丽霞.周国英主任治疗糖尿病肾病的经验总结.福建中医药[J],2005,36(6)：14.
44.肖相如.著名肾病学家时振声教授系列经验之八糖尿病肾病的证治经验.辽宁中医杂志[J].1998,25(8)：346.
45.冯健春,倪青.时振声教授治疗糖尿病肾病经验述要[M].1996,23(12)：534-535.
46.倪青,时振声.糖尿病肾病辨证论治体会.中医函授通讯[G],1997,16(1)：11-12.
47.吕仁和主编.糖尿病及其并发症中西医诊治学.第1版.北京：人民卫生出版社[M]，1997,330-334.
48.吕仁和,赵进喜.糖尿病肾病临床研究述评,北京中医药大学学报[R],1994,17,(2)：2-6.
49.王越.吕仁和用“六对论治”诊治糖尿病及其并发症的经验.中国医药学报[N],1998,13(4)：46-49.
50.戴京璋,吕仁和,赵进喜,等.糖尿病肾病中医证治.北京中医药大学学报[N],2002,25(5)：65-66.
51.刘铜华,郑鸿雁.糖尿病肾病的中医药诊治述要.国际中医中药杂志[J]，2006,28(3)：187-190.
52.牟新,宋美玲.赵进喜教授治疗糖尿病肾病经验介绍.新中医[J],2005,37(11)：15-16.
53.吕仁和,赵进喜，王世东.糖尿病及其并发症的临床研究.新中医[J]，2001,33(3)：3-5.
54.赵进喜主编.内分泌代谢病中西医诊治.第1版.沈阳：辽宁科学技术出版社[N],2004,198-214.
55. Burrows.Morb Mortal Wkly Rep 200_5,54(43):1097
56.杨春,许杜秋，张岭尿微量蛋白检测对糖尿病肾病早期诊断的临床意义.标记免疫分析与临床(R),2002,9 (1):56-57.57. DCCT Research Group. Lifetime benefits and costs of intensive therapy aspracticed in the diabetes control and complications trial. JAMA 1996.276:1409-1415.58. DCCT Research Group. Lifetime benefits and costs of intensive therapy aspracticed in the diabetes control and complications trial.JAMA 1996,276:1409-1415.59. Harold Metal. Early dietary protein restriction slows diseaseprogression and lengthens survival in mice with polycystic kidney disease. AmSoc Nephrol,1994; 5:1355.
60.丁学屏.中西医结合糖尿病学.人民卫生出版社(J).2004,242-244.
61. Vora JP. Anderson S, Brenner BM. Pathogenesis of diabetic glome rulopathy:the role of glomerular hemodynamic factors. In:CE Mogensen, ed. The Kidney and Hypertension in Diabetes Mellitus,2nd edn. Kluwer Academic Publishers,1994,223-231.
62. Liu FA,Cogan MG. Role of protein kinase C in proximal bicarbonateabsorptionand angiotensin signaling. Am J Physiol,1990,258:F927-F933.138.Haneda M, Kikkawa R, Suginmoto A, et al. Abnormalities in protein kinaseC and MAP kinase cascade in mesangial cells cultred under high glucoseconditions. Diabetes Compl,1995,9:246-248.
63. Tada H 2003; 23 (6):532-43.Isogai S.The fibronectin production is increased bythrombospondin via activation of TGF-beta in cultured human mesangialcells[J].Nephron,1998,79(1):38-43.
64. Mogensen CE. Early Diabetic Renal Involvement and Nephropathy. In:AlbertiKGMM, Krall LP. The Diabtes Annual. Vol 3, Amsterdam. Elsevier Science publishers,1987; 306.
65. The diabetes control and complications Trial Research group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Eng J Med,1993,329:977-986.
66. UK Prospective Diabetes Study (UKPDS) group. Intensive blood glucose control with sulphonylureaor insulin compared with conventional treatment and risk of complications inpatients with type2 diabetes.Lancet,1998,325:837-853.
67. Ruilope LM.Luno J. Angiotensin blockade in type2 diabetic renal diseases. Kidney Int Suppl, 2002,82:61-63.
68. Forbes JM,Thorpe SR,Thallas-Bonke V,etal. Modulation of soluble receptor foradvanced glycation end products by angiotensin-converting enzyme-1 inhibition indiabetic nephropathy. Jam Soc Nephrol, 200-5,16(8):2363-2372.
69. Remuzzi G,Macia M.Ruggenenti P. Prevention and Treatment of Diabetic RenalDisease in Type 2 Diabetes:The BENEDICT Study J Am Soc Nephrol.2006Apr.17:90-9788. Yamagishi S,Takeuchi M,moue H.Olmesartanmedoxomil, a newly developed angiot-ensin Ⅱ type 1 receptor antagonist, protects against renal damage in advanced glycation end product(age)-injected rats. Drugs Exp Clin Res,200-5,31(2):451
70. ChaDR. Kang YS.Han SY, etal. Role of aldosterone in diabetic nephropathy.Nephrology (Canton),200-5,10(2):S37-S39.
71. Rachmani R, Slavachevsky IAmit M.etal.The effect of spironolactone, cilaz april and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction:a randomized controlled study [J] Diabetic Med,2004,21(5):471-475.
72. Ota T, Takamura T, Ando H, etal. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia,2003,46 (6):843-851.
73. EndoK,Miyashita Y.S as akiH,etal. Probucol delays progression of diabeticnephropathy. Diabetes Res Clin Pract.200-5:8.
74.堪贻璞.糖尿病肾病的诊断与治疗,西藏医药杂志(J).2004,25(1)：24-27.
75.江涛,陈孟华.糖尿病肾病的透析治疗.肾脏病与透析肾移植杂志(J),2003.12(4)：350-351.
76.叶任高,许韩师.尿溶菌酶和尿N—乙酞—β-D-氨基葡萄糖苷酶测定对肾小管间质病变的诊断价值.中国实用内科杂志,1999,19(J)：198-199
77.董砚虎.逢少男,等.黄芩治疗糖尿病肾病疗效观察.山东医药,1998,(12)：7
78.柯凌.大黄的药理及其在肾脏病中的运用.中国中西医结合肾病杂志.2001,2(J)347-348
79.宁英远,王俭勤,等.大黄素对人肾成纤维细胞增殖的影响.中国中西医结合杂志,2000,20(J)：105-106
80.李伟,陈颖莉,等.玉米须降血糖的实验研究.中草药,1995，26(J)：305-308
81.王鼎,郭蓉.玉米须利尿作用的初步研究.内蒙古中医药,1991,(J)：38
82.曾小玲.玉米须、蒲公英和茵陈篙水煎液的抗氧自由基作用.中国现代医学杂志,1999,9(J)：22-23
83.尹仁杰,吴继洲.泽泻的研究进展,医药导报，2003,22(N)：295-296
84.杨新波,黄正明,等.泽泻水醇提取物对链脉佐菌素诱发小鼠糖尿病的保护作用.北京军医学院学报,2000,9(N)：36-37
85.种军,袁秀荣.怀牛膝药理作用研究进展.中医研究,1999,12(N)：56-58
86.阮金兰,杜俊蓉,等.益母草的化学、药理和临床研究进展。中草药.2003，34(N)：15-19
2.毛黎明,俞东容,涂晓.辨证与辨病相结合治疗糖尿病肾病32例.浙江中医学院学报,25(N)：17-18.
3.张甲臣.浅谈糖尿病肾病的中医治疗.河南中医,1999,19(J)：21.
4.周恩庆.王西周老师治疗糖尿病肾病经验介绍.陕西中医,2001,22(J)：225-226.
5.陈以平.肾病的辨证与辨病治疗.人民卫生出版社(J),2003,147-148.
6.沈稚舟,吴松华,邵福源，陈国辉主编.糖尿病慢性并发症.上海：上海医科大学出版社(J),1999,175-176.
7.吕贵德.辨证论治糖尿病肾病38例疗效观察.河北中医(J),2002,24：103-104.
8.刘从明，何金霞.辨证治疗糖尿病肾病临床观察.内蒙古中医药(J),1996,3：4-6.
9.张珍先,宋小平.糖尿病肾病的辨证施治.光明中医(J),2006,21(1)：16.
10.成秀梅.任琢珊治疗糖尿病肾病的经验.陕西中医(J),2003,24(10)：921.
11.鲁盈,楼狄.糖尿病肾病的诊断与中医治疗.浙江中西医结合杂志(J).1997,7(4)：201-203.
12.邓经林.48例糖尿病肾病的中医辨证论治.江西中医药(N),2001,32(5)：29.
13.郑庆媛.糖尿病肾病辨证分型论治.实用中医内科杂志(J)。2003,17(2)：72.
14.王改勤,姚丽,张寒梅.辨证治疗糖尿病肾病体会.江西中医药(J)，2004,35(8)：49.
15.傅能,赵韧.中西医结合治疗早期糖尿病肾病临床观察.现代中西医结合杂志(J),2006,15(8)：989.
16.罗月中.叶任高教授治疗糖尿病肾病的经验.中国中西医结合肾病杂志(J),2001,2(8)438-440.
17.郭连川.辨证治疗糖尿病性肾病54例.辽宁中医杂志(J),1993,3：19-20.
18.赵宗江.叶传蕙教授治疗糖尿病肾病的思路与方法.中国中西医结合肾病杂志(J),2006,7(3)：129-131.
19.张庚良.糖尿病肾病的辨证治疗.河北中医(S),2005,27(8)：594.
20.苏小惠,戴舜珍.中西医结合治疗糖尿病肾病40例临床观察.辽宁中医杂志(J),2006,33(1)92-93.
21.仝小林,张志远,李宁.等.糖尿病肾病的中医治疗.中国医药学报(N),1998,13(4)50-53.
22.南一,南红梅,何泽.南征教授治疗消渴肾病(糖尿病肾病)的经验.长春中医学院学报(N),2004,20(3)：8-9.
23.宋述菊,牟宗秀.糖尿病肾病病因病机及辨治探讨.山东中医杂志(J),1999,18(4)147-148.
24.张玉璞,刘玉英.辨证治疗糖尿病肾病.河北中医(S),1999,21(5)：292.
25.赵会贤,苏荣华,高新业.糖尿病肾病的病因病机及证治浅识.中医药学刊(J),2004,22(9)：1760-1763.
26.张瑞彬,糖尿病肾病中医辨治体会.河南中医,2003年,23(9)：66-67.
27.于晓光,王业丽,张琪.张琪教授辨治糖尿病肾病经验介绍.陕西中医(S),2004,25(12)：1116-1118.
28王晓光,王业丽.张佩清.张琪教授辨治糖尿病肾病经验介绍新中医[N],2005年37(3)20-21
29.梁炜,李世华.糖尿病肾病的发病机理和辨治思路.四川中医[N],2003,21(7)：7-8.
30.李大钧,范克.糖尿病肾病的中医辨证治疗.河北中医[S],2001,23(9)：682.
31.王立新.杨霓芝主任医师治疗糖尿病肾病经验拾萃.中医药研究[J],2000,16(6)：36.
32.杨霓芝,李芳,徐大基,等,糖尿病肾病分期辨证治疗的探讨,辽宁中医杂志[J],1999,26(1)：16-17.
33.詹锐文,李敬.糖尿病肾病的中医分型辨治浅析.实用中医内科杂志[J],2004,18卷(6)：566-567.
34.丁学屏.糖尿病病治疗方法举要.世界中医药学会联合会糖尿病专业委员会第二次国际中医糖尿病学术交流会论文集[A],2006,104-106.
35.林兰.糖尿病中西医结合论治.北京：北京科学技术出版社[M],1997,404-407.
36.倪青.著名中医学家林兰教授学术经验系列之四病机以气阴两虚为主治疗当益气养阴为先—治疗糖尿病肾病的经验整理.辽宁中医杂志[J],2000,27(4)：145-146.
37.孙炜.早期糖尿病肾病的中医辨证治疗.浙江中医学院学报[J],1999,2(4)：14.
38.董兴刚.张庆怡治疗早期糖尿病肾病临床经验.浙江中西医结合杂志,2005,15(12)751.
39.孙伟,何伟明.糖尿病肾病蛋白尿的中医药治疗体会.江苏中医药,2002,23(5)18-19.
40.任爱华,剥方旭.糖尿病肾病二焦辨治,山东中医杂志[J].2000,19(6)：328-329.
41.高阳,李琪.刘启庭辨治糖尿病肾病经验.河南中医[M],1997,17(1)：31-32.
42.张彤.名医经验叶景华主任治疗糖尿病肾病的临床经验.中医药信息[J],2003,20(3)：29-30.
43.翁荃,张丽霞.周国英主任治疗糖尿病肾病的经验总结.福建中医药[J],2005,36(6)：14.
44.肖相如.著名肾病学家时振声教授系列经验之八糖尿病肾病的证治经验.辽宁中医杂志[J].1998,25(8)：346.
45.冯健春,倪青.时振声教授治疗糖尿病肾病经验述要[M].1996,23(12)：534-535.
46.倪青,时振声.糖尿病肾病辨证论治体会.中医函授通讯[G],1997,16(1)：11-12.
47.吕仁和主编.糖尿病及其并发症中西医诊治学.第1版.北京：人民卫生出版社[M]，1997,330-334.
48.吕仁和,赵进喜.糖尿病肾病临床研究述评,北京中医药大学学报[R],1994,17,(2)：2-6.
49.王越.吕仁和用“六对论治”诊治糖尿病及其并发症的经验.中国医药学报[N],1998,13(4)：46-49.
50.戴京璋,吕仁和,赵进喜,等.糖尿病肾病中医证治.北京中医药大学学报[N],2002,25(5)：65-66.
51.刘铜华,郑鸿雁.糖尿病肾病的中医药诊治述要.国际中医中药杂志[J]，2006,28(3)：187-190.
52.牟新,宋美玲.赵进喜教授治疗糖尿病肾病经验介绍.新中医[J],2005,37(11)：15-16.
53.吕仁和,赵进喜，王世东.糖尿病及其并发症的临床研究.新中医[J]，2001,33(3)：3-5.
54.赵进喜主编.内分泌代谢病中西医诊治.第1版.沈阳：辽宁科学技术出版社[N],2004,198-214.
55. Burrows.Morb Mortal Wkly Rep 200_5,54(43):1097
56.杨春,许杜秋，张岭尿微量蛋白检测对糖尿病肾病早期诊断的临床意义.标记免疫分析与临床(R),2002,9 (1):56-57.57. DCCT Research Group. Lifetime benefits and costs of intensive therapy aspracticed in the diabetes control and complications trial. JAMA 1996.276:1409-1415.58. DCCT Research Group. Lifetime benefits and costs of intensive therapy aspracticed in the diabetes control and complications trial.JAMA 1996,276:1409-1415.59. Harold Metal. Early dietary protein restriction slows diseaseprogression and lengthens survival in mice with polycystic kidney disease. AmSoc Nephrol,1994; 5:1355.
60.丁学屏.中西医结合糖尿病学.人民卫生出版社(J).2004,242-244.
61. Vora JP. Anderson S, Brenner BM. Pathogenesis of diabetic glome rulopathy:the role of glomerular hemodynamic factors. In:CE Mogensen, ed. The Kidney and Hypertension in Diabetes Mellitus,2nd edn. Kluwer Academic Publishers,1994,223-231.
62. Liu FA,Cogan MG. Role of protein kinase C in proximal bicarbonateabsorptionand angiotensin signaling. Am J Physiol,1990,258:F927-F933.138.Haneda M, Kikkawa R, Suginmoto A, et al. Abnormalities in protein kinaseC and MAP kinase cascade in mesangial cells cultred under high glucoseconditions. Diabetes Compl,1995,9:246-248.
63. Tada H 2003; 23 (6):532-43.Isogai S.The fibronectin production is increased bythrombospondin via activation of TGF-beta in cultured human mesangialcells[J].Nephron,1998,79(1):38-43.
64. Mogensen CE. Early Diabetic Renal Involvement and Nephropathy. In:AlbertiKGMM, Krall LP. The Diabtes Annual. Vol 3, Amsterdam. Elsevier Science publishers,1987; 306.
65. The diabetes control and complications Trial Research group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Eng J Med,1993,329:977-986.
66. UK Prospective Diabetes Study (UKPDS) group. Intensive blood glucose control with sulphonylureaor insulin compared with conventional treatment and risk of complications inpatients with type2 diabetes.Lancet,1998,325:837-853.
67. Ruilope LM.Luno J. Angiotensin blockade in type2 diabetic renal diseases. Kidney Int Suppl, 2002,82:61-63.
68. Forbes JM,Thorpe SR,Thallas-Bonke V,etal. Modulation of soluble receptor foradvanced glycation end products by angiotensin-converting enzyme-1 inhibition indiabetic nephropathy. Jam Soc Nephrol, 200-5,16(8):2363-2372.
69. Remuzzi G,Macia M.Ruggenenti P. Prevention and Treatment of Diabetic RenalDisease in Type 2 Diabetes:The BENEDICT Study J Am Soc Nephrol.2006Apr.17:90-9788. Yamagishi S,Takeuchi M,moue H.Olmesartanmedoxomil, a newly developed angiot-ensin Ⅱ type 1 receptor antagonist, protects against renal damage in advanced glycation end product(age)-injected rats. Drugs Exp Clin Res,200-5,31(2):451
70. ChaDR. Kang YS.Han SY, etal. Role of aldosterone in diabetic nephropathy.Nephrology (Canton),200-5,10(2):S37-S39.
71. Rachmani R, Slavachevsky IAmit M.etal.The effect of spironolactone, cilaz april and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction:a randomized controlled study [J] Diabetic Med,2004,21(5):471-475.
72. Ota T, Takamura T, Ando H, etal. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia,2003,46 (6):843-851.
73. EndoK,Miyashita Y.S as akiH,etal. Probucol delays progression of diabeticnephropathy. Diabetes Res Clin Pract.200-5:8.
74.堪贻璞.糖尿病肾病的诊断与治疗,西藏医药杂志(J).2004,25(1)：24-27.
75.江涛,陈孟华.糖尿病肾病的透析治疗.肾脏病与透析肾移植杂志(J),2003.12(4)：350-351.
76.叶任高,许韩师.尿溶菌酶和尿N—乙酞—β-D-氨基葡萄糖苷酶测定对肾小管间质病变的诊断价值.中国实用内科杂志,1999,19(J)：198-199
77.董砚虎.逢少男,等.黄芩治疗糖尿病肾病疗效观察.山东医药,1998,(12)：7
78.柯凌.大黄的药理及其在肾脏病中的运用.中国中西医结合肾病杂志.2001,2(J)347-348
79.宁英远,王俭勤,等.大黄素对人肾成纤维细胞增殖的影响.中国中西医结合杂志,2000,20(J)：105-106
80.李伟,陈颖莉,等.玉米须降血糖的实验研究.中草药,1995，26(J)：305-308
81.王鼎,郭蓉.玉米须利尿作用的初步研究.内蒙古中医药,1991,(J)：38
82.曾小玲.玉米须、蒲公英和茵陈篙水煎液的抗氧自由基作用.中国现代医学杂志,1999,9(J)：22-23
83.尹仁杰,吴继洲.泽泻的研究进展,医药导报，2003,22(N)：295-296
84.杨新波,黄正明,等.泽泻水醇提取物对链脉佐菌素诱发小鼠糖尿病的保护作用.北京军医学院学报,2000,9(N)：36-37
85.种军,袁秀荣.怀牛膝药理作用研究进展.中医研究,1999,12(N)：56-58
86.阮金兰,杜俊蓉,等.益母草的化学、药理和临床研究进展。中草药.2003，34(N)：15-19